Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV299 Safety and Antiviral Activity in RSV Challenge Model
NCT06067191Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RV299 with Placebo (2 arms). Primary endpoint: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR). Started Aug 2022; status: completed.
02
Drugs
RV299
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06067191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067191.